Inicio
Press Release: RPG & PIVOTAL
Spanish-based CRO expands the organization’s reach to Spain and enhances its depth of oncology expertise
Austin, Texas and Madrid, Spain, July 22, 2010 - ResearchPoint Global (RPG) announces its newest member, Pivotal S.L., a full-service, 110-strong, Spanish CRO and medical pharmaceutical consultancy group. As a leading CRO in Spain, Pivotal´s most salient features are its organization by therapeutic areas, the presence of a medical and pharmacovigilance hub with 7 medical employees and a strong Data Management/Biostatistics division based on the fully integrated Oracle Health Sciences Suite, including Oracle Clinical, RDC, Siebel CTMS and ARGUS Safety. Although Pivotal serves all therapeutic areas, they have considerable experience within onco-hematology, cardiovascular, anti-infectives, immunology and CNS.
“As RPG continues to strategically expand its global footprint, Pivotal allows us to better serve our current and prospective clients, especially in oncology, with their extensive expertise that is second to none in Europe. In addition, we are now able to offer clients deep local knowledge and a significant clinical resource base in both Spain and Portugal”, said John Farinacci, Chairman of ResearchPoint Global.
Matt Walker, Executive Vice President of Marketing and Business Development with ResearchPoint, commented “I am excited about this new partnership, since it will not only strengthen RPG, both directly in Western Europe for the conduct of clinical trials, but also across all regions, as we leverage Pivotal’s medical team and expertise in certain therapeutic areas for the benefit of our clients’ protocol reviews and other program design efforts.”
RPG’s expansion into Spain offers several advantages for successfully running clinical trials, including a high number of world-renowned investigators and proven investigational sites, universal national health coverage, a well organized regulatory process and an experienced clinical research team composed of CRAs and Project Managers. Spain is considered a major hub for the implementation of trials in certain therapeutic areas, such as oncology, acute cardiology, infectious diseases and AIDS.
“We´re delighted to become part of the RPG family, since this will give Pivotal the geographic breadth via the RPG established partnership, while Pivotal will provide the therapeutic depth, a specialized medical hub and a well established DMBS group”, commented Dr. Ibrahim Farr, MD, PhD, FFPM(UK), Pivotal´s Founder, Chairman and CEO. “We have enjoyed for several years a double digit growth and have become a reference CRO in our region. While having a strong presence in Spain, we have successfully implemented and managed trials across the western European countries, such as Portugal, Italy, France and the UK”, concluded Dr. Farr.
About ResearchPoint Global
ResearchPoint Global (RPG) is a worldwide clinical organization with 24 regional offices and coverage in 65 countries. As a proven global organization, RPG involves truly local resources to navigate regional issues and consists of high-performing teams whose principals are actively engaged in the success of each clinical program. Pivotal S.L. complements RPG’s current presence in the Americas, Africa, Europe (Western, Central, and Eastern), and India. Visit www.researchpointglobal.com for more information.
About Pivotal S.L.
Pivotal is the leading privately held Spanish based Contract Research Organization (“CRO”) with a solid presence across Western Europe (directly, via partners or known contractors). The Company has 10 years of experience and an unrivalled track record of delivering all ranges of clinical research services to multinational and local Pharmaceutical and Biotechnological companies. Pivotal has successfully grown its business organically since it was founded in November 2001 developing clinical trials in all therapeutic areas with a special emphasis on Oncology, Cell Therapy, Acute Cardiovascular, Diabetes, Central Nervous System, Immune-based, Infectious and other disease areas. Visit www.pivotal.es for more information.
